Adrian Rawcliffe, Adaptimmune

James No­ble is tak­ing his last lap at the biotech he found­ed, and saved. It's Adri­an Raw­clif­fe's turn now

Back in the sum­mer of 2014, Adap­ti­m­mune CEO James No­ble had about a mil­lion pounds in the bank. Not too much to sur­vive on, as he told me lat­er in re­count­ing the tale. But af­ter steer­ing the start­up in and out of a buy­out in or­der to stay in busi­ness, it wasn’t his first look over the cliff.

A few months lat­er Glax­o­SmithK­line stepped up with a $350 mil­lion col­lab­o­ra­tion deal, where it is still ac­tive­ly in­volved in push­ing through a lead­ing pro­gram in the T-cell re­cep­tor (TCR) field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.